> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves Takeda’s Livtencity
- URL: https://www.fdaweb.com/fda-approves-takedas-livtencity/
- Published: 2021-11-24T12:00:00.000Z
- Updated: 2026-09-14T17:23:29.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5150646

FDA has approved Takeda’s Livtencity (maribavir), the first treatment approved by the agency for adults and pediatric patients with post-transplant cytomegalovirus infection that does not respond to available antiviral treatment for the infection. The approval was [announced](https://finance.yahoo.com/news/fda-approves-takedas-livtencity-maribavir-151700818.html?ref=fdaweb.com) by the Brand Institute, which partnered with Takeda in naming the drug.